Views & Analysis Patient power in Europe – more work to be done What the EMA and pharma can do to promote patient involvement in decision making.
News Brexit could delay drug launches, former MHRA chief warns Britain will be in "second or third tier" of drug launches, experts warn.
News Could UK's post-Brexit regulator evaluate value as well? But longer-term benefits could include faster reimbursement decisions.
News Hunt under pressure over plans to quit EMA Britain could be in "second rank" of medicines access, warn MPs.
News EU drug regulators concerned about Brexit impact European regulators concerned over impact of EMA move.
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
